diabetes — diagnosis, targets, and complications
Diagnose diabetes with FPG ≥7.0, A1C ≥6.5%, 2-h OGTT ≥11.1, or random PG ≥11.1 mmol/L with symptoms (confirm once if asymptomatic). Target A1C ≤7.0% for most adults (relax to 7.1–8.5% in frailty/recurrent severe hypoglycaemia), pair with ABCDE vascular protection, and screen microvascular complications at diagnosis in T2DM and at 5 years in T1DM.
Suspected type 1 diabetes (young, lean, rapid weight loss, ketosis) or acute hyperglycaemic crisis: do not use A1C to rule out diabetes (rises too slowly) and do not delay insulin waiting for confirmatory repeat labs → diabetic ketoacidosis — management.
screening, diagnosis, and classification
- Screening (CTFPHC 2012): calculate risk (CANRISK/FINDRISC) every 3–5 years in adults ≥18; do not routinely screen low/moderate risk; screen high risk q3–5 years with A1C; very high risk annually. (Diabetes Canada recommends screening all adults ≥40 q3 years or earlier with risk factors — CTFPHC is more conservative.)
| test | prediabetes | diabetes | caveats |
|---|---|---|---|
| FPG (≥8 h fast) | 6.1–6.9 mmol/L (IFG) | ≥7.0 mmol/L | use FPG + A1C together in older adults |
| A1C (lab, not POC) | 6.0–6.4% | ≥6.5% | invalid in suspected T1DM, pregnancy, or altered RBC turnover |
| 2-h PG (75 g OGTT) | 7.8–11.0 mmol/L (IGT) | ≥11.1 mmol/L | most sensitive in older adults and cystic fibrosis |
| random PG | — | ≥11.1 mmol/L | single test diagnostic only if classic osmotic symptoms present |
- Confirmation: symptomatic hyperglycaemia → 1 abnormal test suffices; asymptomatic → repeat confirmatory test (preferring the same test, except an asymptomatic random PG ≥11.1 mmol/L should be confirmed with an alternate test; if two different tests are both above threshold, diagnosis is confirmed; if discordant, repeat the abnormal test).
| subtype | key clinical clues | confirmatory clue |
|---|---|---|
| T1DM | lean/young (any age), ketosis-prone, rapid progression | anti-GAD / IA-2 / ZnT8 antibodies; low C-peptide |
| LADA | adult onset, initially non-insulin-requiring, progresses to insulin within months–years | anti-GAD positive; lean or normal BMI |
| T2DM | insulin resistance, metabolic syndrome, family history | clinical diagnosis |
| MODY (monogenic) | autosomal dominant (>2 generations), onset <25 years, non-obese, no ketosis, negative antibodies | genetic testing (HNF1A/HNF4A responsive to low-dose SU; GCK mild fasting hyperglycaemia needs no Rx) |
| pancreatogenic (T3c) | chronic pancreatitis, CF, hereditary haemochromatosis, post-pancreatectomy | exocrine insufficiency; loss of both insulin and glucagon → brittle hypoglycaemia |
A1C confounders
A1C reflects mean glucose over 8–12 weeks (~50% from the last 30 days). Use glucose monitoring (or CGM) when A1C is unreliable:
- Falsely elevated A1C: iron or B12 deficiency (prolonged RBC lifespan), splenectomy, alcoholism, uraemia (carbamylated Hb), hyperbilirubinaemia.
- Falsely lowered A1C: haemolysis, acute blood loss, recent transfusion, erythropoietin/iron/B12 replacement (reticulocytosis), splenomegaly, CKD (shortened RBC lifespan), chronic liver disease, hypertriglyceridaemia, dapsone, ribavirin, antiretrovirals.
- Variable: haemoglobinopathies, HbF.
glycaemic and CGM targets
Check A1C every 3 months until stable at target, then every 6 months.
| patient group | A1C target | fasting / preprandial | 2-h postprandial |
|---|---|---|---|
| most adults (T1DM & T2DM) | ≤7.0% | 4.0–7.0 mmol/L (4.0–5.5 if A1C >7% & low hypo risk) | 5.0–10.0 mmol/L (5.0–8.0 if A1C >7% & low hypo risk) |
| T2DM, low hypoglycaemia risk (to ↓ CKD/retinopathy) | ≤6.5% (or <6.0% for remission) | — | — |
| functionally dependent | 7.1–8.0% (or <8.0% if not on insulin/SU) | 5.0–8.0 mmol/L | <12.0 mmol/L |
| frail / dementia / recurrent severe hypo / limited life expectancy | 7.1–8.5% (or <8.5% if not on insulin/SU) | 6.0–9.0 mmol/L | <14.0 mmol/L |
| end of life | do not measure A1C | avoid symptomatic hyperglycaemia and any hypoglycaemia | — |
CGM metrics (DC 2021)
Require ≥70% sensor wear over 14 days. Every 10% increase in time in range (TIR) ≈ 0.5% decrease in A1C.
| metric | most adults (T1DM / T2DM) | older / high-risk for hypoglycaemia | pregnant T1DM |
|---|---|---|---|
| TIR | >70% (3.9–10.0 mmol/L) | >50% (3.9–10.0 mmol/L) | >70% (3.5–7.8 mmol/L) |
| TBR | <4% (<3.9); <1% (<3.0) | <1% (<3.9) | <4% (<3.5: <3% 3.1–3.4, <1% <3.0) |
| TAR | <25% (>10.0); <5% (>13.9) | <10% (>13.9) | <25% (>7.8) |
ABCDE vascular protection
- A — A1C ≤7.0% (early tight control gives legacy CV and microvascular benefit).
- B — BP <130/80 mmHg (Diabetes Canada; ADA 2026 encourages SBP <120 if high CV/kidney risk and tolerated → hypertension).
- C — Cholesterol: statin for clinical CVD, age ≥40, age >30 with duration >15 years, or microvascular disease; intensify if LDL ≥2.0 mmol/L (≥1.8 with ASCVD per CCS → dyslipidaemia).
- D — Drugs for vascular protection:
- ACEi/ARB (at vascular-protective doses: ramipril 10 mg, perindopril 8 mg, telmisartan 80 mg): clinical CVD, age ≥55 with an additional CV risk factor or end-organ damage, or microvascular disease. Reliable contraception is required when prescribing ACEi, ARB, or statins in patients of childbearing potential.
- ASA 81–162 mg daily: established CVD (Grade A against routine primary prevention; may consider in selected patients with additional CV risk factors, Grade D; clopidogrel 75 mg if ASA-intolerant).
- SGLT2i / GLP-1 RA / finerenone: per comorbidity → type 2 diabetes, chronic kidney disease.
- E — Exercise, healthy eating, and smoking cessation.
microvascular complication screening
| complication | when to start | how & frequency | first-line management |
|---|---|---|---|
| retinopathy | T1DM: 5 y post-dx if age ≥15 · T2DM: at diagnosis | dilated fundoscopy or retinal photography by optometrist/ophthalmologist · q1y (T1DM), q1–2y (T2DM if none) | glycaemic + BP control; fenofibrate (added to statin therapy; not for CVD prevention) slows progression of established T2DM retinopathy (Grade A); anti-VEGF / laser / vitrectomy for sight-threatening disease |
| nephropathy | T1DM: 5 y post-dx · T2DM: at diagnosis | annual random urine ACR + eGFR (positive if ACR >20 or ≥2 of 3 >2 mg/mmol, or eGFR <60) | max tolerated RASi + SGLT2i ± finerenone / semaglutide → chronic kidney disease |
| neuropathy | T1DM: 5 y post-pubertal · T2DM: at diagnosis | annual 10 g monofilament or 128 Hz vibration at dorsum of great toe | optimise glycaemia; painful neuropathy: pregabalin (Grade A), gabapentin, duloxetine, amitriptyline, or venlafaxine; topical nitrate spray; opioids last resort |
| foot care | all patients | annual exam (neuropathy, pulses/PAD, skin/callus, deformity); more often if high risk | fitted footwear, prompt offloading + sharp debridement + moist wound care for ulcers; total contact cast for acute Charcot foot; vascular assessment → peripheral arterial disease |
Screen clinically for orthostatic hypotension (SBP drop >20 mmHg), resting tachycardia, gastroparesis, overflow bladder, and erectile dysfunction — cardiac autonomic neuropathy independently predicts mortality.
Prepared 2026-11-19. Not yet verified — check every number against the sources.